InVivo Therapeutics Holdings Corporation
NVIV · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.02 | 0.03 | 0.01 |
| FCF Yield | -65.60% | -58.62% | -111.20% | -46.98% |
| EV / EBITDA | 1.89 | 2.92 | 3.97 | 4.58 |
| Quality | ||||
| ROIC | -29.45% | -16.76% | -17.23% | -14.66% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.85 | 1.27 | 1.37 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 7.16% | 23.78% | -46.06% | 9.17% |
| Safety | ||||
| Net Debt / EBITDA | 3.18 | 5.05 | 5.19 | 6.59 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -153.75 | -274.86 | -485.55 | -470.59 |